NEVVI Medicare utilization intelligence

← back

SAI, PADMAJAM.D. NPI 1013002880 Clinician

Hematology-Oncology · PALM COAST, FL

Specialty Hematology-Oncology — from billed Medicare claims
In practice about 32 years since medical school (class of 1994, self-reported to CMS)
Location PALM COAST, FL · NPPES registered location
Active in data Billed Medicare 2020–2024 (5 consecutive years)
Scale 69 codes billed · 395,139 disclosed services (CY2024 — most recent year in data)
Current groups

Group affiliation since 2019

20192026
FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE, LLC
2019–2026

The roster archive begins in 2019, so a span starting at 2019 may reach back further. Membership spans only — no volume is attributed to any group here.

NPPES registry · CMS Doctors & Clinicians registry · Medicare Part B physician/supplier claims · NPPES record last updated 2022-09

Year: 2024 · 2023 · 2022  · 2021  · 2020 

Provider overview · all codes · CY2024

The full analytics for this provider

Premium

The billed-volume positioning, practice focus, and economics behind this provider — computed on the same disclosed Medicare Part B data.

This provider's disclosed Medicare payments across all codes were in CY2024. Unlock to see the figure.

  • Payment, service & beneficiary totals — the disclosed scale, all codes
  • Practice profile — focus & reach — top codes by share of services
  • Office vs. facility setting mix — place-of-service code split
  • Volume over five years — discrete yearly counts, no rate
  • Peer positioning — service volume — percentile among specialty peers, cohort & year disclosed
  • Peer positioning — code breadth — how many codes billed, vs peers

Peer positioning shows billed-volume and code-breadth positions among specialty peers, not measures of care (a provider's true volume position can only be higher, never lower). All figures disclosed Medicare Part B fee-for-service; volumes are personal to this NPI, not attributed to any group.

Notify me at launch → Or see a live example profile →

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)
J9263 Injection, oxaliplatin, 0.5 mg
J9271 Injection, pembrolizumab, 1 mg
J0897 Injection, denosumab, 1 mg
J0185 Injection, aprepitant, 1 mg
Q5101 Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram
J1756 Injection, iron sucrose, 1 mg
J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj
J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units
J9267 Injection, paclitaxel, 1 mg
Q5129 Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg
J1100 Injection, dexamethasone sodium phosphate, 1 mg
J1434 Injection, fosaprepitant (focinvez), 1 mg
J1437 Injection, ferric derisomaltose, 10 mg
36415 Insertion of needle into vein for collection of blood sample
J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg
85025 Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count
Q5106 Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units
J2469 Injection, palonosetron hcl, 25 mcg
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
96372 Injection of drug or substance under skin or into muscle
J9395 Injection, fulvestrant, 25 mg
J2405 Injection, ondansetron hydrochloride, per 1 mg
J2919 Injection, methylprednisolone sodium succinate, 5 mg
96413 Administration of chemotherapy into vein, 1 hour or less
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
Q5127 Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg
G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg
J9045 Injection, carboplatin, 50 mg
J3489 Injection, zoledronic acid, 1 mg
J9190 Injection, fluorouracil, 500 mg
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
96375 Injection of additional new drug or substance into vein
J1200 Injection, diphenhydramine hcl, up to 50 mg
96415 Administration of chemotherapy into vein, each additional hour
99215 Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more
96417 Administration of additional new drug or substance into vein, 1 hour or less
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
85610 Blood test, clotting time
96374 Injection of drug or substance into vein
J3475 Injection, magnesium sulfate, per 500 mg
99497 Advance care planning, first 30 minutes
96366 Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
81003 Automated urinalysis test
99204 New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more
J9217 Leuprolide acetate (for depot suspension), 7.5 mg
99205 New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more
99211 Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional
99223 Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes
99232 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes
99233 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes
J7030 Infusion, normal saline solution , 1000 cc
G0498 Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l
85045 Red blood count, automated test
96368 Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion
96360 Infusion into a vein for hydration, 31-60 minutes
99195 Drawing of blood for a medical problem
96409 Administration of chemotherapy into vein using push technique
96411 Administration of additional new drug or substance into vein using push technique
J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit)
J2920 Injection, methylprednisolone sodium succinate, up to 40 mg
99496 Transitional care management services for problem of high complexity
96361 Infusion into a vein for hydration, each additional hour
99495 Transitional care management services for problem of at least moderate complexity
99203 New patient office or other outpatient visit with low level of medical decision making, if using time, 30 minutes or more
99406 Smoking and tobacco use intensive counseling, 4-10 minutes

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.